Lower Cost, Better Results, World Renowned Doctor.

Infertile patients cannot afford to wait for treatment while their eggs get older.

Dr. Sherman Silber, Infertility Center of St. Louis, is offering video consultations for patients who need to plan now for their treatment while stay-at-home orders are in place. He is talking to and evaluating patients in their home to comply with social distancing measures.

Dr. Silber is discovering that patients actually prefer this method of telemedicine consultation over the conventional office visit. Patients have conveyed that “it is so much more convenient and less stressful” to have a telemedicine personal consultation than to take a day off from work to travel to the doctor’s office and sit with other nervous patients in the waiting room.

The COVID-19 pandemic is thus changing much of the way we will do things in the future, and for the better. “Our patients are surprisingly much happier with this approach. Of course, at some point we need to perform hands on treatment. But with this new manner of seeing patients, we can come to the right diagnosis and treatment plan for most patients more efficiently, quickly, and painlessly, with no loss of personal one-on-one communication.” This is a very welcome new era of telemedicine that has been forced on us by the current difficult times.

From Microsurgery to Vitrification: Dr. Silber on IVF Innovations & Future Fertility

In this interview-style clip, Dr. Sherman J. Silber introduces himself as the longtime director of a renowned infertility center in St. Louis, Missouri—and, he notes, likely one of the longest-practicing IVF physicians still active today. Trained in urology yet working across both male and female infertility, he describes an unusually broad clinical scope that once included hands-on embryology. Silber recounts his early role in microsurgery and his friendship with Dr. Kuyama, whose vitrification method transformed IVF: before vitrification, slow-freeze techniques damaged embryos and eggs, pushing clinics in the 1980s–1990s to transfer multiple embryos and risk dangerous multiples. Vitrification, he says, “changed everything.”

He traces a major research thread to 1997, when his team began freezing ovarian tissue for cancer patients facing sterilizing treatments. Despite initial doubts—fear of reintroducing cancer cells and no way then to mature eggs in vitro—many of those women later conceived; one patient, he says, has five children from tissue stored since 1997, with grafts lasting about a decade. Current work pursues two parallel paths: transplanting preserved ovarian tissue to restore fertility and hormones, and maturing eggs from that tissue entirely in vitro to avoid even theoretical cancer-cell return.

A second frontier involves reprogramming: making induced pluripotent stem cells from skin biopsies and directing them into primordial germ cells (PGCs), the precursors of eggs. The mouse version already yields healthy offspring; in humans, his lab has generated PGCs—even from women in their mid-50s—and he estimates 10–15 years to functional human oocytes with subsequent regulatory validation.

Silber recalls “happiest memories” of cancer survivors returning decades later with babies. Vitrification’s robustness, he adds, lets clinics freeze eggs young and transfer one embryo at a time without losing viability. His career advice to students is simple: choose passion over pure pragmatism—follow what thrills you, and the dots will connect later.